Vardenafil 5 mg Compared to Other PDE5 Inhibitors

bedaquilinevardenafil and bedaquiline both increase QTc interval.

• Vardenafil 5 mg is not suitable for individuals taking certain heart medications.
• The medication may cause dizziness or lightheadedness in some users.
• Proper storage extends shelf life and maintains potency.
• Lifestyle factors like stress can impact treatment success.
• Avoid heavy meals before taking Vardenafil 5 mg to speed absorption.
• The medication does not work without sexual stimulation.
• Be aware of potential interactions with other prescribed drugs.
• Patients should avoid driving if feeling dizzy after taking it.
• Consult your doctor if you experience prolonged or painful erections.
• Vardenafil 5 mg has a rapid onset but variable duration.
• It is important to review medical history before starting therapy.
• Combination therapy with other ED treatments should only be under medical supervision.

vardenafil and bedaquiline both increase QTc interval. Either increases effects of the other by Mechanism: pharmacodynamic synergism.

What are the differences between vardenafil and tadalafil?

aripiprazole and vardenafil both increase QTc interval. armodafinilarmodafinil will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. armodafinil will decrease the level or effect of vardenafil by affecting best pill for ed hepatic/intestinal enzyme CYP3A4 metabolism. artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether/lumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Related Disease Conditions

asenapinevardenafil increases effects of asenapine by pharmacodynamic synergism. vardenafil increases effects of asenapine by pharmacodynamic synergism. atazanaviratazanavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/24 hr atomoxetineatomoxetine and vardenafil both increase QTc interval. atomoxetine and vardenafil both increase QTc interval. bicalutamidebicalutamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg is a PDE5 inhibitor for erectile dysfunction.
• It helps men achieve and maintain an erection suitable for intercourse.
• Vardenafil 5 mg is often prescribed when other treatments fail.
• This medication can be taken with or without food.
• The effects of Vardenafil 5 mg last about 4-6 hours.
• It is important to follow your healthcare provider’s instructions.
• Avoid high-fat meals close to taking Vardenafil for faster effect.
• Combining Vardenafil 5 mg with recreational drugs is dangerous.
• It may interact with blood pressure medications.
• Do not exceed the prescribed dose to prevent risks.
• Vardenafil 5 mg is generally well-tolerated.
• Always check for contraindications before use.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors bicalutamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors bosentanbosentan will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bosentan will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. budesonidebudesonide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. budesonide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. butalbitalbutalbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. butalbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinibceritinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg may be less effective if taken with high-fat meals.
• Side effects like indigestion or muscle aches are possible.
• Inform your doctor about any allergic reactions experienced.
• Be cautious if you have low blood pressure or heart disease.
• It is recommended to avoid taking other ED medications concurrently.
• Regular check-ups help assess medication effectiveness.
• Discontinue use and seek help if adverse reactions occur.
• The medication can improve intimacy confidence and quality.
• Use the lowest effective dose to minimize side effects.
• Vardenafil 5 mg is generally safe when used responsibly.
• Keep out of reach of children and pets.
• Consult your healthcare provider for personalized advice.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ceritinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors chloramphenicolchloramphenicol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors chloramphenicol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors cimetidinecimetidine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Related/similar drugs

Avoid coadministration of tovorafenib (a weak CYP3A4 inducer) with CYP3A substrates where minimal concentration changes may lead to serious therapeutic failures. If unavoidable, monitor patients for loss of efficacy unless otherwise recommended in the CYP3A4 substrate prescribing information. tovorafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tucatinibtucatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities.

Other Medical Problems

If unavoidable, reduce CYP3A substrate dose according to product labeling. tucatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated. vardenafil increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.

Full form of descriptor (FN): Product containing precisely vardenafil (as vardenafil hydrochloride) 5 mg/1 each conventional release oral tablet (clinical drug) (Atom ID: 11440906)

vilanterol/fluticasone furoate inhaledvardenafil increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. vardenafil increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid coadministration of ziftomenib with other drugs known to prolong the QTc interval. If unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms vardenafil and ziftomenib both increase QTc interval. cimetidine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ECG monitoring is recommended, along with drugs that may prolong the QT interval. clarithromycinclarithromycin will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Available Strengths & Forms

rifabutin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampinrifampin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sevofluranesevoflurane and vardenafil both increase QTc interval. sevoflurane and vardenafil both increase QTc interval.

Incidence not known

silodosinvardenafil increases effects of silodosin by pharmacodynamic synergism. vardenafil increases effects of silodosin by pharmacodynamic synergism. siponimod and vardenafil both increase QTc interval. St John's WortSt John's Wort will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. St John's Wort will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Pulmonary Arterial Hypertension (Orphan)

terazosinvardenafil increases effects of terazosin by pharmacodynamic synergism. vardenafil increases effects of terazosin by pharmacodynamic synergism. tetrabenazinetetrabenazine and vardenafil both increase QTc interval. tetrabenazine and vardenafil both increase QTc interval. tovorafenibtovorafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/24 hr clozapineclozapine and vardenafil both increase QTc interval. clozapine and vardenafil both increase QTc interval. cobicistatcobicistat will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg offers a discreet treatment for erectile issues.
• Its onset of action is approximately 30 minutes after ingestion.
• It should be taken about an hour before intimacy.
• Do not crush or break the tablets; swallow whole.
• Patients should discuss health conditions with their doctor first.
• Vardenafil 5 mg is not a cure but manages symptoms.
• Regular use can improve confidence in sexual activity.
• Use caution if you have heart problems or low blood pressure.
• The medication should not be used by women.
• Safety during activities requiring alertness should be assessed.
• Overdose symptoms may include dizziness or chest pain.
• Always adhere to medical advice when using Vardenafil.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors conivaptan will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors cortisonecortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Additional information

Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms zotepinevardenafil increases effects of zotepine by pharmacodynamic synergism. vardenafil increases effects of zotepine by pharmacodynamic synergism. adagrasibadagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors adagrasib will increase the level or effect of vardenafil by fildena 200 mg affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors alfuzosinvardenafil and alfuzosin both increase QTc interval.

What are the serious side effects of vardenafil?

Use Caution/Monitor.alfuzosin and vardenafil both increase QTc interval. vardenafil and alfuzosin both increase QTc interval. Monitor blood pressure response to phosphodiesterase type 5 (PDE5) inhibitors in patients receiving concurrent blood pressure lowering therapy. amiodaroneamiodarone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors amiodarone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Subscribe to MedicineNet's Men's Health Newsletter

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors apomorphineapomorphine and vardenafil both increase QTc interval. apomorphine and vardenafil both increase QTc interval. aprepitantaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors aprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors aripiprazolearipiprazole and vardenafil both increase QTc interval. cortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

crizotinibcrizotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.